Affimed(US:AFMD)2024-11-14 13:40Clinical Program Updates - AFM24 (ICE® in EGFR+ Solid Tumors): In EGFRwt1 patients, 4 out of 17 showed confirmed responses, with a PFS of 5.9 months; 3 of the 4 responses are ongoing at >7 months[6] - AFM24 (ICE® in EGFR+ Solid Tumors): In EGFRmut2 patients, 4 out of 17 showed confirmed responses; 8 out of 17 patients continue on treatment with 4 out of 4 responders on treatment for at least 7 months[6] - Acimtamig (ICE® for CD30+ Lymphomas): An ORR of 83.3% (10/12) was observed in r/r HL patients, including 6 CRs (50%)[7] - AFM28 (ICE® in AML): 4 out of 12 patients achieved CR/CRi at doses of 250mg and 300mg[9] - AFM28 (ICE® in AML): At DL6, CRc of 50% (3/6) was achieved, leading to the completion of recruitment of an additional 6 patients at DL6[9] Financial Status - Total cash, cash equivalents, and investments as of September 30, 2024, were €24.1 million, compared to €72.0 million as of December 31, 2023[10] - Net cash used in operating activities for the quarter ended September 30, 2024, was €(11.1) million, compared to €(18.3) million for the quarter ended September 30, 2023[11] - Revenue for the quarter ended September 30, 2024, was €0.2 million, compared to €2.0 million for the quarter ended September 30, 2023[12] - Research and development expense for the quarter ended September 30, 2024, was €(10.1) million, compared to €(21.5) million for the quarter ended September 30, 2023[12] - Operating loss for the quarter ended September 30, 2024, was €(14.3) million, compared to €(24.9) million for the quarter ended September 30, 2023[12]